Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The "inhibitory receptor signaling domain" refers to conserved sequence motifs (e.g., ITIM and ITSM) within the cytoplasmic domains of numerous immune inhibitory receptors, including PD-1, CTLA-4, BTLA, SIRPα, Siglecs, and KIRs[2][5][6]. Upon ligand binding, these domains are phosphorylated and recruit SH2 domain-containing phosphatases such as SHP-1, SHP-2, and SHIP, thereby dephosphorylating key signaling proteins and dampening immune cell activation[2][4][5][6]. These motifs play a central role in immune regulation but do not constitute a unique molecular entity; many different receptors use similar domains to inhibit cell signaling. The domain itself is not the druggable target; rather, the inhibitory receptor as a whole is the therapeutic target[2][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Inhibitory receptor signaling domain.